ライフサイエンスコーパス: chelator

1 inhibitors as a pharmacophore rather than a "chelator".

2 abeled with (177)Lu through the CHX-A''-DTPA chelator.

3 uproine disulfonate, a cell-impermeant Cu(I) chelator.

4 4 is fully reversible after treatment with a chelator.

5 s fully reversible by immersing the gel in a chelator.

6 with either vehicle or deferoxamine, an iron chelator.

7 d amounts of either the metal complex or the chelator.

8 he chemical property of vancomycin as a zinc chelator.

9 or the promising anticancer activity of iron chelators.

10 tion when combined with clinically available chelators.

11 simple excess of metals that are targeted by chelators.

12 AOs were weak ferrous ion chelators.

13 or completely rescued using alkaline Ca(2+) chelators.

14 proteins for apo-siderophores, the iron-free chelators.

15 ferrihydrite in the presence and absence of chelators.

16 of sodium chloride with or without the metal chelators.

17 s and this effect can be controlled by metal chelators.

18 tment of cells with the intracellular Ca(2+) chelator 1,2-bis(2-aminophenoxy)ethane-N,N,N',N'-tetraac

19 cells with either the intracellular calcium chelator 1,2-bis(2-aminophenoxy)ethane-N,N,N',N'-tetraac

20 t 37 degrees C, and the intracellular Ca(2+) chelator 1,2-bis(2-aminophenoxy)ethane-N,N,N',N'-tetraac

21 atment of wildtype cochleae with the calcium chelator 1,2-bis(o-aminophenoxy) ethane-N,N,N',N'-tetraa

22 eath is blocked by the intracellular calcium chelator 1,2-bis(o-aminophenoxy)ethane-N,N,N',N'-tetraac

23 inhibitor of phospholipase C or the calcium chelator 1,2-bis(o-aminophenoxy)ethane-N,N,N',N'-tetraac

24 Pretreatment with the Ca(2+) chelator 1,2-bis(o-aminophenoxy)ethane-N,N,N',N'-tetraac

25 in endothelial cells loaded with the Ca(2+) chelator 1,2-bis(o-aminophenoxy)ethane-N,N,N',N'-tetraac

26 antagonists were synthesized by coupling the chelator 1,4,7,10-tetraazacyclododecane-1,4,7,10-tetraac

27 dioimmunoconjugates employing the ubiquitous chelator 1,4,7,10-tetraazacyclododecane-1,4,7,10-tetraac

28 80 kDa) format were functionalized with the chelator 1,4,7-triazacyclononane-1-glutaric acid-4,7-dia

29 Furthermore, either the [Ca(2+)]i chelator(1,2-bis(o-aminophenoxy)ethane-N,N,N',N'-tetraac

30 ibitory concentrations of the synthetic iron chelator 2,2'-dipyridyl.

31 nent system (TCS) and the TCS-regulated iron chelator 2-isocyano-6,7-dihydroxycoumarin (ICDH-Coumarin

32 Herein, we present an octadentate chelator 3,4,3-(LI-1,2-HOPO) (or HOPO) as a potentially

33 The binding of three closely related chelators: 5-hydroxy-2-methyl-4H-pyran-4-thione (allothi

34 sing desferrithiocin, a natural product iron chelator (a siderophore), as a platform for structure-ac

35 Calcium chelators act similarly and mitochondrially targeted ant

36 es and mouse cells, mutation of Ctr1, and Cu chelators all reduce the ability of the MAP kinase kinas

37 A chemical genetic screen revealed that iron chelators alleviate P. aeruginosa-mediated killing.

38 Unfortunately, therapeutic iron chelators also have undesired toxicity and may deliver i

39 re characterized, after conjugation to a DFO chelator and (89)Zr radiolabeling, in assays including c

40 H2O)](-) was modified to form a bifunctional chelator and 4 chelates were conjugated to a fibrin-spec

41 lloprotease inhibitors relies on a core zinc chelator and a peptidic or nonpeptidic scaffold that pro

42 affinity using a modified nitrilotriacetate chelator and exhibits an almost 6 order of magnitude dec

43 helating agent and the linker moiety between chelator and pharmacophore, which influence the overall

44 AC-10 was conjugated with a DFO B chelator and radiolabeled with (89)Zr to give formulated

45 uide for selecting the optimal match between chelator and radiometal for use in these systems.

46 beta-cyclodextrin (HPbetaCD), a cholesterol chelator and the only promising treatment for NPC1.

47 al pH and to investigate the effects of iron chelators and alpha-tocopherol on this process.

48 lays impaired growth in the presence of iron chelators and increased production of the virulence fact

49 ions have been performed with water-soluble chelators and indicators that typically require careful

50 st efficient free-radical scavengers, Fe(2+) chelators and inhibitors of malondialdehyde production,

51 onse under normoxic conditions, such as iron chelators and inhibitors of prolyl hydroxylase domain (P

52 roved management of iron overload using oral chelators and non-invasive MRI measurements, and point-o

53 Iron chelators and other antioxidants have not completely suc

54 53 expression, which was abrogated by Ca(2+) chelators and short hairpin RNA-mediated knockdown of Cn

55 Iron chelators and the inhibitor of the mitochondrial Ca(2+)

56 des were synthesized, conjugated to a copper chelator, and radiolabeled with (64)Cu.

57 y addition of a slight excess of a palladium chelator, and the interaction can be reversibly switched

58 The use of antioxidants, metal chelators, and heme ligands reveals that nitration is co

59 ent cell death (ferroptosis) as well as iron chelators, and thus creates a metabolic vulnerability th

60 model is more suitable for SOSDEs with metal chelator antioxidants e.g. EDTA, than free radical scave

61 lkiness of the residues at the tetramic acid chelator are decisive for the stereochemical outcome.

62 One of the most promising classes of iron chelators are alpha-N-heterocyclic thiosemicarbazones wi

63 The experimental methods by which chelators are assessed for their suitability with a vari

64 ection of the most common and most promising chelators are evaluated and discussed for their potentia

65 conditions, these high-affinity ferric iron chelators are excreted by bacteria in the soil to acquir

66 Two new iron chelators are in development, one in phase 3 clinical tr

67 vels, we required a high-affinity rapid zinc chelator as well as an extracellular ratiometric fluores

68 bodies with 2 forms of DOTA as well as other chelators as controls.

69 90 inhibition, we propose CPX and other iron chelators as investigational antitumor agents in NB ther

70 ed antagonists, modified with DOTA or NODAGA chelators at positions Lys(27) and Lys(40) and labeled w

71 Conjugation of DOTA and NODAGA chelators at positions Lys(27) and Lys(40) of Ex(9-39)NH

72 genetic mutations or exposure to the Ca(2+) chelator BAPTA can, however, still respond to mechanical

73 he intracellular concentration of the Ca(2+) chelator BAPTA caused smaller increases in resting open

74 reatment of MDA-MB-231 cells with the Ca(2+) chelator BAPTA or an inhibitor of endoplasmic reticulum

75 in the cells; effects mitigated by [Ca(2+)]i chelator BAPTA, calcineurin/NFAT inhibitor VIVIT, and TR

76 entry, cells were incubated with the calcium chelator BAPTA-AM (1,2-bis(o-aminophenoxy)ethane-N,N,N',

77 Since the fast Ca(2+) chelator BAPTA-AM inhibits LFD but the slow chelator EGT

78 rinergic receptor agonist PPADS, the calcium chelator BAPTA-AM, and calpain inhibitors.

79 nd such an effect is prevented by the Ca(2+) chelator BAPTA-AM.

80 lycaconitine (MLA) and intracellular calcium chelator BAPTA.

81 n inhibitor N-ethylmaleimide and the calcium chelator BAPTA.

82 nase kinase 2 inhibitor (STO-609) or calcium chelator (BAPTA-AM).

83 By contrast, calcium chelator BAPTM/AM and MEK inhibitor (U0126) can reverse

84 transferase) was conjugated to the metal ion chelator benzyl-diethylenetriaminepentaacetic acid to al

85 Using a metal ion chelator beta-thujaplicinol as a molecular probe, we obs

86 escribed herein are a series of bifunctional chelators (BFCs), L1-L5, that were designed to tightly b

87 The small molecule metal ion chelators bipyridine and terpyridine complexed with Zn(2

88 maintaining, basal Ca(2+) levels with Ca(2+) chelators blocks LTD and drives strong synaptic potentia

89 ogenic microorganisms secrete small molecule chelators called siderophores defined by their ability t

90 Bacteria use tight-binding, ferric-specific chelators called siderophores to acquire iron from the e

91 eviously discovered that small-molecule zinc chelators called zinc metallochaperones (ZMCs) reactivat

92 nst CaMKII activation data in the absence of chelators, CaMKII activation dynamics due to synaptic in

93 partments using cell-penetrating multivalent chelator carrier complexes.

94 semiessential amino acid and a potent metal chelator, CAT4 orthologs could be considered as candidat

95 We found that BAPTA-based calcium chelators cause immediate depolymerization of spindle mi

96 nown short cyclic peptide to a cross-bridged chelator (CB-TE2A), followed by labeling with copper-64.

97 lioma cells (Bmax, 4.28 x 10(7) molecules of chelator/cell; and Kd, 2.45 muM).

98 -phenylbutyrate (4-PBA), as well as the iron chelator ciclopirox (CPX), which reduces ER stress, alle

99 This effect was rescued with the Zn(2+) chelators clioquinol or TPEN.

100 floxacin, and enrofloxacin are powerful iron chelators comparable with deferoxamine, a clinically use

101 overall binding mode of all three metal ion chelator complexes, the pyridine ring of ZnClTerp blocks

102 rmed in the reaction were labeled with metal chelators complexing rare earth metal ions.

103 Chelator conjugation was confirmed by electrospray ioniz

104 pi electrons of graphene without the need of chelator conjugation, providing a promising alternative

105 Certain siderophores-bacterial iron chelators-consist of paired catechol and lysine function

106 give a general overview of protein and metal chelator coordination environments in neurodegenerative

107 ineffective extracellular hydroxypyridinone chelator, CP40.

108 Deferasirox is an orally effective iron (Fe) chelator currently used for the treatment of iron-overlo

109 ere restored upon administration of the iron chelator deferasirox or hyperexpression of Fpn1 or Nrf2.

110 bel" administration of the FDA-approved iron chelator deferiprone evidenced significant reductions in

111 not alter the beneficial effect of the iron chelator deferiprone on iron overload.

112 Treatment of NZB/W mice with the iron chelator deferiprone significantly delayed the onset of

113 This study evaluated whether the iron chelator, deferiprone, is well tolerated, able to chelat

114 , and reduced following addition of the iron chelator deferoxamine (DFO).

115 xtrahepatic protoporphyria) or with the iron chelator deferoxamine and the porphyrin precursor 5-amin

116 Retro-orbital infusion of PP-IX or the iron chelator deferoxamine mesylate (DFO), with the first com

117 nfold increase in susceptibility to the iron-chelators deferoxamine and salicylhydroxamic acid.

118 nedioxythiophene) (PEDOT) into which an iron chelator, deferoxamine (DFA), has been doped during the

119 transferrin or the membrane-impermeable iron chelator, deferoxamine mesylate salt, was able to increa

120 Pigs were also treated with an iron chelator, deferoxamine, (50mg/kg, i.m.) or vehicle and k

121 xtracts was compared to those of three metal chelators; deferoxamine mesylate (DFO), 1,10-phenanthrol

122 ons, Fe(3+), using a gamma-pyrone derivative chelator, demonstrate subpicomolar limit of detection wi

123 Exposure to the iron chelator desferrioxamine decreased SPH forming efficienc

124 Conversely, the classical iron chelator desferrioxamine induced autophagosome accumulat

125 hepatoma cell lines incubated with the iron chelator desferrioxamine resulted in PC7 down-regulation

126 as also demonstrated with the classical iron chelator, desferrioxamine (DFO), and was not observed fo

127 ented as an alternative to the gold standard chelator, desferrioxamine (DFO).

128 Experiments with the strong Mn(III) chelator, desferrioxamine B (DFB), in seawater indicated

129 ite-specifically derivatized with the (89)Zr chelator desferroxamine B via a 3.4-kDa PEG linker.

130 glycyl-glycyl-glycyl-cysteine peptide-based chelator (designated ZHER2:V2) has the best biodistribut

131 n of such effect in the presence of the iron chelator dexrazoxane.

132 The selective antitumor and antimetastatic chelator di-2-pyridylketone 4,4-dimethyl-3-thiosemicarba

133 The chelator di-2-pyridylketone 4,4-dimethyl-3-thiosemicarba

134 We observed that the chelator, di-2-pyridylketone 4,4-dimethyl-3-thiosemicarb

135 that could be partially rescued by the iron chelator dipyridyl.

136 s but restored after the addition of an iron chelator dipyridyl.

137 ssing the catalytic activity, with different chelators displaying different deceleration capacities.

138 and hAb131) were conjugated with the (64)Cu-chelator DOTA through lysine, cysteine, or oligosacchari

139 The chelator DOTA was used in all cases.

140 Metal ion chelating resin, or the chelators EDTA and desferrioxamine decreased monatin and

141 on of high concentrations of the slow Ca(2+)-chelator EGTA, but EGTA had no effect in synaptotagmin-7

142 2+) is depleted by the high-affinity calcium chelator EGTA, suggesting that the calcium present in th

143 chelator BAPTA-AM inhibits LFD but the slow chelator EGTA-AM does not, the Ca(2+) sensor for LFD may

144 Similarly, perfusion of the Ca(2+) chelator EGTA-AM into the slice progressively eliminated

145 atively accounted for in the presence of the chelators EGTA and BAPTA without additional adjustments

146 When combined with these chelators, ELT enhanced cellular iron mobilization more

147 jugation to a maleimido derivative of a DOTA chelator, enabling radionuclide labeling, (1)(1)(1)In fo

148 strongly and systemically, while the Ca(2+) chelator ethylene glycol tetraacetic acid (EGTA) signifi

149 onses could be activated by a synthetic iron chelator ethylenediamine-di(o-hydroxyphenylacetic) acid,

150 Affinity constants derived for the chelator/Fe(3+) complexation as well as for other ions d

151 the triazacyclononane-triphosphinate (TRAP) chelator, followed by automated (68)Ga labeling.

152 8, FBP10) or NOTA-monoamide (FBP9, FBP11) as chelators, followed by labeling with (64)Cu (FBP8 and FB

153 An improved chelator for (89)Zr(4+) could eliminate the release of o

154 errioxamine (DFO) is currently the preferred chelator for (89)Zr(4+); however, accumulation of (89)Zr

155 nstrate that tricine, considered a preferred chelator for studying the role of synaptic zinc, is unab

156 ,7-triazonan-1-yl)pentanedioic acid (NODAGA) chelators for (68)Ga and (64)Cu labeling.

157 organic substances which can act as powerful chelators for dissolved iron and thus enhance its export

158 ed with phosphonate-containing cross-bridged chelators for evaluation of using them as PET imaging ra

159 Unfortunately, progress in developing chelators for medicinal applications has been hindered b

160 ansporters, transcription factors, and metal chelators for metal uptake or exclusion.

161 ion-selective nanospheres as indicators and chelators for optical titrations.

162 tis and diabetes, they may be promising zinc chelators for the treatment of other health disorders in

163 ants for Cu(2+) and Zn(2+) and thus are good chelators for these metal ions.

164 These results indicate that chelators found in U contaminated sites may play a signi

165 a newly developed, fast and highly specific chelator-free approach.

166 The aim of this study is to explore chelator-free labeling of LDH nanoparticles with radiois

167 e of magnetic field gradients; using a novel chelator-free method, the nanoparticles were radiolabele

168 d by light-triggered release of calcium or a chelator from liposomes.

169 d also causes sensitivity to the lipophillic chelator fusaric acid; sacB causes sensitivity to sucros

170 ay before equilibrium (eqMRI) of the Gd(III) chelator Gd.DTPA, via the intraperitoneal route, was use

171 nctional derivative of the versatile acyclic chelator H4octapa, p-SCN-Bn-H4octapa, has been synthesiz

172 rations and concentrations of the endogenous chelators haptoglobin, hemopexin, and alpha1- microglobu

173 This mitochondria-targeted iron chelator has therefore promising potential for skin phot

174 increased copper in tumors, and thus copper chelators have been used to inhibit tumor angiogenesis.

175 Macrocyclic chelators have been widely employed in the realm of nano

176 bitor Glu-NH-CO-NH-Lys(Ahx) using the (68)Ga chelator HBED-CC (PSMA(HBED)) allows imaging of prostate

177 ulates biosynthesis of flagella and the iron chelator ICDH-Coumarin whose production requires the pvc

178 enteroids, administration of excess Cu or Cu chelators impaired assembly of chylomicrons.

179 s promote reoxidation whereas strong Fe(III) chelators impede it.

180 tol hexakisphosphate (IP6), is the main iron chelator in cereals and bread.

181 ey intermediate for CB-TE2A, a commonly used chelator in positron emission tomography medical imaging

182 become a high-affinity transition metal ion chelator in the extracellular space where it inhibits mi

183 l Ca(II) gradients to become a potent Zn(II) chelator in the extracellular space.

184 jugating DFO reduces the cytotoxicity of the chelator in the macrophage cells.

185 our knowledge, the possibility of microbial chelator in the practical development of Al(3+) selectiv

186 s use of iron-binding chemistry of microbial chelators in order to functionalize the surface of iron

187 Thiosemicarbazone chelators, including the 2'-benzoylpyridine thiosemicarb

188 Nicotianamine, a copper chelator, increased by 12-27 fold compared to the contro

189 bstitution experiments with synthetic Ca(2+) chelators indicated the presence of endogenous Ca(2+) bu

190 As thiosemicarbazone chelators induce stress and up-regulate NDRG1 to inhibit

191 ma MCF-7 cells, we found that TEPA, a copper chelator, inhibited EMT-like cell morphology and cytoske

192 receptor-conserved Glu-283(VII:06/7.39) Both chelators interact with aromatic residues in the transme

193 These results suggest that choice of chelator is an important pharmacokinetic consideration i

194 dies in the search for an orally active iron chelator is thoroughly developed.

195 ac iron by the 3 commercially available iron chelators is summarized for cardiac iron overload withou

196 Currently, radiolabeling through macrocyclic chelators is the most commonly used strategy.

197 concentration of pyoverdine, a secreted iron chelator, is heterogeneous, with a maximum at the center

198 tic acid (BAPTA-AM), an intracellular Ca(2+) chelator known to deplete ER Ca(2+) stores.

199 for extracellular iron using strain-specific chelators known as siderophores.

200 The degree of inhibition by the cis Ca(2+) chelator largely depended on increasing trans Ca(2+).

201 rney from O-donor through S-donor to N-donor chelator led to the development of a highly selective Au

202 in situ) than the reduced heme site, and (3) chelators like clioquinol remove Cu from these aggregate

203 argeted hexadentate (tricatechol-based) iron chelator linked to mitochondria-homing SS-like peptides.

204 The solution to the problem, chelator-mediated iron removal, is clear.

205 nographene was observed, which revealed that chelator-mediated nanoparticle-based PET imaging has its

206 les (MNPs) conjugated with actinide specific chelators (MNP-Che) is reviewed with a focus on design a

207 cane-1,4,7,10-tetraacetic acid) or DOTA-like chelator-modified peptide.

208 ide (NaCl)-based method for radiolabeling of chelator-modified peptides for molecular imaging.

209 However, most gadolinium (Gd)-chelator MR contrast agents are limited by their relativ

210 lation of Zn(2+) with the membrane-permeable chelator N,N,N',N'-Tetrakis(2-pyridylmethyl)ethylenediam

211 inc concentration by treatment with the zinc chelator N,N,N'-tetrakis-(2'-pyridylmethyl)ethylenediami

212 caffold and utilize a variety of macrocyclic chelators, namely NOTA(3), PCTA(4), Oxo-DO3A(5), CB-TE2A

213 were expressed in hypnozoites and the copper chelator neocuproine was cidal to all liver stage parasi

214 Content of the metal chelator nicotianamine (NA) in the root of zinc hyperacc

215 f Arabidopsis unable to synthesize the metal chelator nicotianamine.

216 tide synthesis and elongated with respective chelators (NODA-GA, DOTA) for (68)Ga-labeling or proparg

217 HOPO has the potential to replace DFO as the chelator of choice for (89)Zr-based PET imaging agents.

218 ely, they were decreased by treatment with a chelator of divalent cations.

219 Glycyrrhizin, a chelator of HMGB-1 and a blocking antibody to receptor f

220 nhibitor of NO synthesis, or carboxy-PTIO, a chelator of NO.

221 es show that the ligand is a much more rapid chelator of Th(4+) than prevailing ligands (1,4,7,10-tet

222 ) carrying BBB-permeable neuropeptides and a chelator of the positron emitter (68)Ga as a PET reporte

223 we have assessed whether high-affinity iron chelators of the pyridoxal isonicotinoyl hydrazone (PIH)

224 re employed to investigate the effect of the chelator on the biodistribution and PCa tumor uptake pro

225 Studies concerning the influence of chelators on biodistribution of (99m)Tc-labeled Affibody

226 Addition of an intracellular calcium chelator or an AMPK inhibitor to either mouse macrophage

227 Remarkably, when recruited via chelator or anionic lipids, respectively, the reengineer

228 Mice treated with a mitochondrial iron chelator or mice fed a low-iron diet were protected from

229 signal, while breaking tip links with Ca(2+) chelators or blocking Ca(2+) entry through transduction

230 d CA3, as indicated by the ability of Zn(2+) chelators or Ca(2+) entry blockers to delay pyramidal ne

231 nt cells treated with antioxidants or Ca(2+) chelators or cultured in low oxygen markedly reduced the

232 Either calcium chelators or inhibitors of voltage-gated L-type calcium

233 ily mitigated by addition of nontoxic copper chelators or N-acetylcysteine, indicating a role for cop

234 llular Ca(2+) elevation through either caged chelators or pharmacological inhibitors of Ca(2+) effect

235 ved no more than 24 months of treatment with chelators or zinc, had a Leipzig score of 4 or more, and

236 The chelator p-SCN-Bn-DFO was conjugated to AMG102, radiolab

237 eruginosa and to treatment with a xenobiotic chelator, phenanthroline, in C. elegans.

238 These findings identify the chelator phytate as an intracellular bacteriostatic comp

239 role that organic compounds such as Fe(III) chelators play in the stability of reduced U.

240 Siderophores are small-molecule iron chelators produced by bacteria and other microorganisms

241 bactericide compounds by siderophores (iron chelators produced by bacteria) is a promising strategy

242 Siderophores are high-affinity iron chelators produced by microorganisms and frequently cont

243 eaction modeling suggests that strong Fe(II) chelators promote reoxidation whereas strong Fe(III) che

244 rate of UO(2) reoxidation occurred when the chelator promoted both UO(2) and Fe(III) (hydr)oxide dis

245 ional negative charges (carboxylates) on the chelator, promoting renal clearance.

246 dizing activity in the presence of a Mn(III) chelator, pyrophosphate, we found that the complex facil

247 positions) of pyrazolyl-diamine bifunctional chelators (Pz(2)-Pz(4)) on the pharmacokinetic profile o

248 Ammonium tetrathiomolybdate (ATTM), a copper chelator, releases sulfide in a controlled and novel man

249 ects of EGTA and BAPTA (slow and fast Ca(2+) chelators, respectively) suggest that the acidic organel

250 Experiments with exogenous Ca(2+) chelators reveal that channel-sensor coupling at basket

251 her, studies using a membrane-permeable iron chelator, salicylaldehyde isonicotinoyl hydrazone, revea

252 r other radiometals that could use a similar chelator/scaffold combination for radiopharmaceutical th

253 ddition, from an intricate sample, the novel chelator shows exceptional specificity toward fluoride a

254 Mycobactins are small-molecule iron chelators (siderophores) produced by Mycobacterium tuber

255 Small molecule iron-chelators, siderophores, are very important in facilitat

256 A membrane-permeable iron chelator substantially reduces NMDA excitotoxicity, sugg

257 ivation has stimulated the treatment with Zn chelators, such as diethyldithiocarbamate (DEDTC).

258 ween plant tissues is facilitated by organic chelators, such as nicotianamine and citrate.

259 nd ethylene glycol tetraacetic acid (calcium chelator) suggested existence of intermediate molecule(s

260 The CN + HP killing is blocked by iron chelators, suggesting Fenton's reaction.

261 the ability to grow in media containing iron chelators, suggesting the presence of additional pathway

262 Siderophores are specific ferric iron chelators synthesized by virtually all microorganisms in

263 ivity, with a time response dependent on the chelator tested.

264 Of the 17 iron chelators tested, six reduced cell viability of two NB c

265 We conclude that ELT is a powerful iron chelator that decreases cellular iron and further enhanc

266 ry, a PTPmu-targeted peptide was linked to a chelator that had been conjugated to a lysine residue.

267 d small molecule deferoxamine (DFO), an iron chelator that increases HIF-1alpha transactivation in di

268 molecule by conjugation of BIST to a Ca(2+) chelator that upon laser flash photolysis rapidly releas

269 reduce iron accumulation is the use of iron chelators that are able to cross the blood-brain barrier

270 e thiosemicarbazone (TSC) class of metal ion chelators that bind iron, copper, magnesium, zinc, and o

271 The typical metal ion chelators that can be used for radiolabeling reactions h

272 Quinolinols are known chelators that can disrupt the BoNT/A metalloprotease zi

273 the active secretion of protons and organic chelators that enhance calcium dissolution at fungal-min

274 hnetium complexes with tetradentate tripodal chelator (the tris(2-mercaptoethyl)amine (NS3)) and the

275 radiometal-based radiopharmaceutical is the chelator, the ligand system that binds the radiometal io

276 ell as development of environmentally benign chelators, this method could become very flexible and co

277 Due to the highly selective chelators, this remediation method could be both simple

278 iodine radiolabeling with an azamacrocyclic chelator to confer residualizing properties on the radio

279 set of examples of rationally designed metal chelators to outcompete this deleterious binding will be

280 have been the difficulty in finding suitable chelators to stably attach it to targeting vehicles such

281 The successful search for orally active iron chelators to treat transfusional iron-overload diseases,

282 The radionuclide (90)Y was coupled by the chelator trans-cyclohexyl-diethylene-triamine-pentaaceti

283 On the basis of the (68)Ga chelators TRAP (triazacyclononane-triphosphinate) and NO

284 Methods: On the basis of the (68)Ga chelators TRAP (triazacyclononane-triphosphinate) and NO

285 reduction of copper with the clinical copper chelator TTM inhibits MEK1/2 kinase activity and reduces

286 Cu chelators used in the treatment of Wilson disease decrea

287 The chelator was conjugated to the HER2/neu-targeting antibo

288 the optical and NMR titrations analysis, the chelator was found to be highly selective for fluoride c

289 Addition of a metal ion chelator was found to reverse the assembly of the hollow

290 The intracellular calcium chelator was used to examine whether the intracellular c

291 tazolamide, a spacer, and a peptidic (99m)Tc chelator, was labeled using sodium pertechnetate under r

292 Three pyrazolyl-diamine-containing chelators were conjugated to betaAlaNleCycMSHhex, with t

293 The new generation chelators were conjugated to Tyr3-octreotate (Y3-TATE) t

294 sine pharmacophores conjugated to CIM or TIM chelators were radiolabeled with (99m)Tc and evaluated i

295 ylmethyl) ethylenediamine, a specific Zn(2+) chelator, whereas nontumorigenic esophageal epithelial c

296 ational states, rather than active site iron chelators, which make up most reported 2OG oxygenase inh

297 h a thiol-reactive fluorescent dye and via a chelator with a radionuclide.

298 conjugate of a tris(hydroxypyridinone) (THP) chelator with the established urea-based PSMA inhibitor

299 isotherms of Ca(2+) binding to a mixture of chelators with and without residual ligand present in th

300 host or other bacteria through specific iron chelators with high binding affinity.